JNJ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Johnson & Johnson is a stable, large-cap stock with strong fundamentals and a positive long-term growth outlook. However, given the mixed financial performance in the latest quarter, insider selling, cautious congressional trading activity, and lack of strong technical buy signals, it is recommended to hold off on buying at this time. For a beginner investor with a long-term strategy, waiting for a more favorable entry point or additional positive catalysts might be prudent.
The MACD is below zero and negatively contracting, indicating bearish momentum. RSI is neutral at 39.964, and moving averages are converging, suggesting no strong directional trend. The stock is trading near its support level of 226.201, with resistance at 240.323.
Analysts have raised price targets and remain optimistic about JNJ's long-term growth, driven by strong product pipelines and recent approvals like Icotyde.
News highlights the company's stability and consistent dividend payments, making it attractive for long-term investors.
Positive clinical trial results for Nipocalimab and Imaavy indicate strong R&D progress.
Insider selling has increased significantly by 159.20% over the last month, indicating potential caution from company executives.
Congress members have shown a cautious stance with two recent sale transactions and no purchases.
Financial performance in Q1 2026 shows a significant drop in net income (-52.40%) and EPS (-52.86%), despite revenue growth.
In Q1 2026, revenue grew by 9.91% YoY to $24.06B, driven by strong product uptake. However, net income and EPS declined sharply by -52.40% and -52.86%, respectively, indicating margin pressures or increased costs. Gross margin remained stable at 66.46%.
Analysts are generally positive, with multiple firms raising price targets (ranging from $250 to $285) and maintaining Buy or Overweight ratings. Key drivers include strong product pipelines, double-digit growth in pharma, and MedTech stability. However, some firms maintain Neutral or Hold ratings, citing 'okay' earnings and sector-wide challenges.
